We are pleased with the settlement agreement recently announced with GLUMETZA. Under this agreement Lupin has granted the right to begin selling a generic version of GLUMETZA on February 1, 2016. We believe we are taking the right step to lengthen the runway to continue growing GLUMETZA prescriptions and revenues, while advancing our development pipeline.CYCLOSET net sales in the fourth quarter were $3.8 million, up approximately 81% over third quarter 2011 net sales. We expect the product will continue to growth in 2012 with increased call frequency by our larger sales organization. Turning to our development programs starting with UCERIS. Our NDA for UCERIS was accepted for review by the FDA in mid-February following its submission in December. This sets the PDUFA date for completion of the FDA review at October 16, 2012. We believe that UCERIS has the potential to be an important new therapeutic option in the treatment of ulcerative colitis, a chronic disease that afflicts an estimated 600,000 to 700,000 patients in the U.S.
Santarus' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.